(ICLR) ICON - Ratings and Ratios
Clinical Trials, Laboratory Services, Data Solutions, Consulting, Patient Access
ICLR EPS (Earnings per Share)
ICLR Revenue
Description: ICLR ICON
ICON PLC (NASDAQ:ICLR) is a clinical research organization providing outsourced development and commercialization services globally, with a strong presence in Ireland, Europe, and the US. The company offers a comprehensive range of services, including clinical trial management, consulting, and laboratory services, catering to the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
From a business perspective, ICONs diversified service portfolio and global footprint position it well for growth. The companys ability to provide adaptive trials, decentralized and hybrid clinical trials, and real-world intelligence services is particularly noteworthy, as these services address the evolving needs of the life sciences industry. With a strong track record of delivering high-quality services, ICON has established itself as a trusted partner for clients.
Examining key performance indicators (KPIs), ICONs revenue growth rate, customer acquisition rate, and client retention rate are crucial metrics to monitor. The companys return on equity (RoE) of 7.90% indicates a relatively stable return on shareholder investment. Additionally, the forward price-to-earnings (P/E) ratio of 10.58 suggests that the market expects earnings growth, potentially driven by increasing demand for outsourced clinical research services. Other important KPIs to consider include the companys operating margin, net promoter score, and employee utilization rate, which can provide insights into ICONs operational efficiency and competitiveness.
To further evaluate ICONs investment potential, it is essential to analyze its financial statements, including revenue segmentation, gross margin trends, and cash flow generation. A review of the companys management team, corporate governance, and industry trends can also provide valuable context. By examining these factors, investors can gain a more comprehensive understanding of ICONs strengths, weaknesses, and growth prospects.
ICLR Stock Overview
| Market Cap in USD | 13,614m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1998-05-15 |
ICLR Stock Ratings
| Growth Rating | -45.4% |
| Fundamental | 64.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -51.0% |
| Analyst Rating | 4.29 of 5 |
ICLR Dividends
Currently no dividends paidICLR Growth Ratios
| Growth Correlation 3m | 73.2% |
| Growth Correlation 12m | -82% |
| Growth Correlation 5y | 1.6% |
| CAGR 5y | -5.10% |
| CAGR/Max DD 3y | -0.08 |
| CAGR/Mean DD 3y | -0.50 |
| Sharpe Ratio 12m | -1.07 |
| Alpha | -54.09 |
| Beta | 0.719 |
| Volatility | 49.29% |
| Current Volume | 1597.4k |
| Average Volume 20d | 1057.4k |
| Stop Loss | 167.2 (-4.5%) |
| Signal | 0.47 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (794.2m TTM) > 0 and > 6% of Revenue (6% = 485.4m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -0.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.30% (prev 10.34%; Δ -1.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.17b > Net Income 794.2m (YES >=105%, WARN >=100%) |
| Net Debt (3.16b) to EBITDA (1.37b) ratio: 2.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (79.5m) change vs 12m ago -4.58% (target <= -2.0% for YES) |
| Gross Margin 27.36% (prev 24.29%; Δ 3.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.20% (prev 49.10%; Δ -0.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.89 (EBITDA TTM 1.37b / Interest Expense TTM 202.5m) >= 6 (WARN >= 3) |
Altman Z'' 1.57
| (A) 0.05 = (Total Current Assets 3.31b - Total Current Liabilities 2.56b) / Total Assets 16.60b |
| (B) 0.15 = Retained Earnings (Balance) 2.56b / Total Assets 16.60b |
| (C) 0.06 = EBIT TTM 989.5m / Avg Total Assets 16.79b |
| (D) 0.35 = Book Value of Equity 2.50b / Total Liabilities 7.05b |
| Total Rating: 1.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.59
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 6.03% = 3.01 |
| 3. FCF Margin 12.40% = 3.10 |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda 2.49 = -0.93 |
| 6. ROIC - WACC -0.27% = -0.33 |
| 7. RoE 8.28% = 0.69 |
| 8. Rev. Trend 46.31% = 2.32 |
| 9. Rev. CAGR 1.39% = 0.17 |
| 10. EPS Trend 59.51% = 1.49 |
| 11. EPS CAGR 6.36% = 0.64 |
What is the price of ICLR shares?
Over the past week, the price has changed by +0.07%, over one month by +3.50%, over three months by +18.97% and over the past year by -41.61%.
Is ICON a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ICLR is around 147.88 USD . This means that ICLR is currently overvalued and has a potential downside of -15.5%.
Is ICLR a buy, sell or hold?
- Strong Buy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ICLR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 216.8 | 23.9% |
| Analysts Target Price | 216.8 | 23.9% |
| ValueRay Target Price | 162.9 | -6.9% |
Last update: 2025-08-30 04:44
ICLR Fundamental Data Overview
CCE Cash And Equivalents = 390.4m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 18.0093
P/E Forward = 13.0548
P/S = 1.6829
P/B = 1.4162
P/EG = 1.2558
Beta = 1.17
Revenue TTM = 8.09b USD
EBIT TTM = 989.5m USD
EBITDA TTM = 1.37b USD
Long Term Debt = 3.38b USD (from longTermDebt, last quarter)
Short Term Debt = 29.8m USD (from shortTermDebt, last quarter)
Debt = 3.41b USD (Calculated: Short Term 29.8m + Long Term 3.38b)
Net Debt = 3.16b USD (from netDebt column, last quarter)
Enterprise Value = 16.64b USD (13.61b + Debt 3.41b - CCE 390.4m)
Interest Coverage Ratio = 4.89 (Ebit TTM 989.5m / Interest Expense TTM 202.5m)
FCF Yield = 6.03% (FCF TTM 1.00b / Enterprise Value 16.64b)
FCF Margin = 12.40% (FCF TTM 1.00b / Revenue TTM 8.09b)
Net Margin = 9.82% (Net Income TTM 794.2m / Revenue TTM 8.09b)
Gross Margin = 27.36% ((Revenue TTM 8.09b - Cost of Revenue TTM 5.88b) / Revenue TTM)
Tobins Q-Ratio = 6.65 (Enterprise Value 16.64b / Book Value Of Equity 2.50b)
Interest Expense / Debt = 1.47% (Interest Expense 50.2m / Debt 3.41b)
Taxrate = 8.94% (77.7m / 869.2m)
NOPAT = 901.0m (EBIT 989.5m * (1 - 8.94%))
Current Ratio = 1.29 (Total Current Assets 3.31b / Total Current Liabilities 2.56b)
Debt / Equity = 0.36 (Debt 3.41b / last Quarter total Stockholder Equity 9.56b)
Debt / EBITDA = 2.49 (Net Debt 3.16b / EBITDA 1.37b)
Debt / FCF = 3.40 (Debt 3.41b / FCF TTM 1.00b)
Total Stockholder Equity = 9.59b (last 4 quarters mean)
RoA = 4.78% (Net Income 794.2m, Total Assets 16.60b )
RoE = 8.28% (Net Income TTM 794.2m / Total Stockholder Equity 9.59b)
RoCE = 7.63% (Ebit 989.5m / (Equity 9.59b + L.T.Debt 3.38b))
RoIC = 6.92% (NOPAT 901.0m / Invested Capital 13.01b)
WACC = 7.19% (E(13.61b)/V(17.03b) * Re(8.66%)) + (D(3.41b)/V(17.03b) * Rd(1.47%) * (1-Tc(0.09)))
Shares Correlation 3-Years: 7.63 | Cagr: -0.33%
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.24% ; FCFE base≈1.07b ; Y1≈1.08b ; Y5≈1.17b
Fair Price DCF = 237.5 (DCF Value 18.47b / Shares Outstanding 77.8m; 5y FCF grow 0.69% → 3.0% )
Revenue Correlation: 46.31 | Revenue CAGR: 1.39%
Rev Growth-of-Growth: -7.05
EPS Correlation: 59.51 | EPS CAGR: 6.36%
EPS Growth-of-Growth: -14.02
Additional Sources for ICLR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle